Simplified 510(k)s for radiation therapy, ultrasound, nuclear imaging rejected by FDA.
This article was originally published in The Gray Sheet
Executive Summary
SIMPLIFIED 510(K)S NIXED FOR RADIATION THERAPY, NUCLEAR AND ULTRASOUND imaging due to a lack of comprehensive standards for the devices, Joe Levitt, FDA Center for Devices and Radiological Health deputy director for regulations and policy, said Sept. 18 at the National Electrical Manufacturers Association annual meeting in Vail, Colorado. Levitt told NEMA members that FDA will not accept the association's proposal to allow simplified 510(k)s attesting compliance with voluntary standards because CDRH reviewers have concluded that the standards "get to part of your 510(k), not all."
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.